Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nexera Technologies LtdNEXR · Entity 8617 | Director | March 18, 2026 | May 07, 2026 |
| Polyrizon Ltd.PLRZ · Entity 7474 | Director | March 31, 2026 | April 01, 2026 |
| Rail Vision Ltd.RVSN · Entity 7971 | Director | March 18, 2026 | March 18, 2026 |
| SciSparc Ltd.SPRC · Entity 8412 | CEO and CFO | March 18, 2026 | July 13, 2026 |
| Wearable Devices Ltd.WLDS · Entity 8228 | Director | August 13, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nexera Technologies Ltd
Report date March 18, 2026 · Filed May 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase ordinary sharesSEC Table I · non-derivative | Direct | 1,450 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 1,450 F1: Represents (i) 2 ordinary shares, (ii) 1,448 restricted share units ("RSUs") Granted on September 16, 2025 and the vesting commencement date is September 10, 2025, which vest in equal quarterly installments of 12.5% beginning on December 10, 2025, of which 362 RSUs have vested and 1,086 remain unvested as of March 18, 2026; and (ii) 8,100 RSUs granted on January 1, 2026, which vest in equal quarterly installments of 12.5% beginning on January 1, 2026, all of which remain unvested as of March 18, 2026. |
| Ordinary warrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43,749.20 · Expires 2027-08-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) 2 ordinary shares, (ii) 1,448 restricted share units ("RSUs") Granted on September 16, 2025 and the vesting commencement date is September 10, 2025, which vest in equal quarterly installments of 12.5% beginning on December 10, 2025, of which 362 RSUs have vested and 1,086 remain unvested as of March 18, 2026; and (ii) 8,100 RSUs granted on January 1, 2026, which vest in equal quarterly installments of 12.5% beginning on January 1, 2026, all of which remain unvested as of March 18, 2026.
Polyrizon Ltd.
Report date March 31, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,850 |
Reported balance
After 2026-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-31 · Sale · Disposed 3,292 · Balance 19,850 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.1041, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Consists of (1) 3,363 ordinary shares, (2) 29 restricted ordinary shares that vest in equal installments on a monthly basis, subject to the Reporting Person's continued service, and (3) 16,458 restricted ordinary shares that vest in equal installments on a quarterly basis, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.1041, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Consists of (1) 3,363 ordinary shares, (2) 29 restricted ordinary shares that vest in equal installments on a monthly basis, subject to the Reporting Person's continued service, and (3) 16,458 restricted ordinary shares that vest in equal installments on a quarterly basis, subject to the Reporting Person's continued service.
Rail Vision Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,152 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,152 |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 973 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 973 F1: These restricted share units vest in 7 equal installments on a quarterly basis beginning on March 31, 2026, subject to the Reporting Person's continued service. F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Rail Vision Ltd. Amended Share Option Plan must be registered in the name of a trustee. |
| Restricted Share UnitsSEC Table I · non-derivative | Direct | 1,375 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,375 F2: These restricted share units vest in 9 equal installments on a quarterly basis beginning on March 31, 2026, subject to the Reporting Person's continued service. F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Rail Vision Ltd. Amended Share Option Plan must be registered in the name of a trustee. |
| Options to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $444.00 · Expires 2032-06-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Rail Vision Ltd. Amended Share Option Plan must be registered in the name of a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted share units vest in 7 equal installments on a quarterly basis beginning on March 31, 2026, subject to the Reporting Person's continued service.
F2: These restricted share units vest in 9 equal installments on a quarterly basis beginning on March 31, 2026, subject to the Reporting Person's continued service.
F3: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Rail Vision Ltd. Amended Share Option Plan must be registered in the name of a trustee.
SciSparc Ltd.
Report date March 18, 2026 · Filed July 13, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 11,058 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 11,058 F1: This Form is filed solely as an amendment to the Form 3 filed on March 18, 2026. This amendment amends and restates the first footnote in Table I as follows: "Includes (i) 10,000 ordinary shares, no par value per share, of the Issuer (the "Ordinary Shares") issuable upon the vesting of restricted share units ("RSUs") in quarterly installments of 1,250 Ordinary Shares through December 18, 2027; and (ii) 1,058 Ordinary Shares issuable upon the vesting of RSUs in equal quarterly installments of 132 Ordinary Shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share." |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31,941.00 · Expires 2028-01-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed F2: In addition, this amendment amends and restates Table II of the initial Form 3, as provided herein. No amendment is made hereby to any other footnotes of the initial Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form is filed solely as an amendment to the Form 3 filed on March 18, 2026. This amendment amends and restates the first footnote in Table I as follows: "Includes (i) 10,000 ordinary shares, no par value per share, of the Issuer (the "Ordinary Shares") issuable upon the vesting of restricted share units ("RSUs") in quarterly installments of 1,250 Ordinary Shares through December 18, 2027; and (ii) 1,058 Ordinary Shares issuable upon the vesting of RSUs in equal quarterly installments of 132 Ordinary Shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share."
F2: In addition, this amendment amends and restates Table II of the initial Form 3, as provided herein. No amendment is made hereby to any other footnotes of the initial Form 3.
Wearable Devices Ltd.
Report date August 13, 2026 · Filed August 20, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 1, 2026 20:15 UTC | Polyrizon Ltd. PLRZ · Entity 7474 | SaleOrdinary Shares | 3,292 | $12.05 | $39,668.60 |
DisclosureSEC source: 0001213900-26-038525 · ownership.xml · nonDerivative · entry 1 Adler Oz · CIK 0001973096 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,850 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.1041, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Consists of (1) 3,363 ordinary shares, (2) 29 restricted ordinary shares that vest in equal installments on a monthly basis, subject to the Reporting Person's continued service, and (3) 16,458 restricted ordinary shares that vest in equal installments on a quarterly basis, subject to the Reporting Person's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.